Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Bausch + Lomb Corporation ( (BLCO) ) is now available.
On July 21, 2025, Bausch + Lomb Corporation amended the employment agreement with CEO Brenton L. Saunders, limiting his severance rights related to the company’s spin-off from Bausch Health Companies Inc. Additionally, the company adjusted the terms of Saunders’ performance stock units, setting a new vesting schedule and performance targets to be achieved by February 23, 2029, which could impact the company’s financial incentives and executive compensation strategy.
The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s stock score is primarily influenced by its financial performance and technical analysis. While the company shows strong market positioning and growth in key segments, profitability and cash flow issues weigh heavily. Technical indicators are favorable, but nearing overbought levels. The valuation remains weak, primarily due to negative earnings. However, recent corporate events and resilient earnings call outcomes provide some positive outlook.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation operates in the healthcare industry, focusing primarily on eye health products and services. The company is known for its wide range of contact lenses, lens care products, and ophthalmic pharmaceuticals.
Average Trading Volume: 825,912
Technical Sentiment Signal: Hold
Current Market Cap: $5.05B
Find detailed analytics on BLCO stock on TipRanks’ Stock Analysis page.